Gatselis Nikolaos K, Zachou Kalliopi, Saitis Asterios, Samara Maria, Dalekos George N
Nikolaos K Gatselis, Kalliopi Zachou, Asterios Saitis, George N Dalekos, Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, 41110 Larissa, Greece.
World J Gastroenterol. 2014 Mar 21;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839.
Hepatitis C virus (HCV) infection is a global health problem that affects more than 170 million people worldwide. It is a major cause of cirrhosis and hepatocellular carcinoma, making the virus the most common cause of liver failure and transplantation. The standard-of-care treatment for chronic hepatitis C (CHC) has been changed during the last decade and direct acting antiviral drugs have already been used. Besides, understanding of the pathogenesis of CHC has evolved rapidly during the last years and now several host factors are known to affect the natural history and response to treatment. Recent genome-wide association studies have shown the important role of interleukin-28B and inosine triphosphatase in HCV infection. The present review article attempts to summarize the current knowledge on the role of host factors towards individualization of HCV treatment.
丙型肝炎病毒（HCV）感染是一个全球性的健康问题，全球有超过1.7亿人受其影响。它是肝硬化和肝细胞癌的主要病因，使该病毒成为肝衰竭和肝移植最常见的原因。在过去十年中，慢性丙型肝炎（CHC）的标准治疗方法已经改变，直接作用抗病毒药物已被使用。此外，近年来对CHC发病机制的认识迅速发展，现在已知有几种宿主因素会影响其自然病程和对治疗的反应。最近的全基因组关联研究表明白细胞介素-28B和肌苷三磷酸酶在HCV感染中的重要作用。本综述文章试图总结目前关于宿主因素在HCV治疗个体化中作用的知识。
